

REFERENCE TITLE: clinical research; psilocybin; grants; appropriation

State of Arizona  
House of Representatives  
Fifty-sixth Legislature  
First Regular Session  
2023

## **HB 2486**

Introduced by  
Representatives Payne, Longdon, Travers, Senator Shope

### **AN ACT**

**AMENDING TITLE 36, CHAPTER 2, ARIZONA REVISED STATUTES, BY ADDING ARTICLE 5; REPEALING TITLE 36, CHAPTER 2, ARTICLE 5, ARIZONA REVISED STATUTES; APPROPRIATING MONIES; RELATING TO RESEARCH GRANTS.**

(TEXT OF BILL BEGINS ON NEXT PAGE)

1 Be it enacted by the Legislature of the State of Arizona:

2 Section 1. Title 36, chapter 2, Arizona Revised Statutes, is  
3 amended by adding article 5, to read:

4 ARTICLE 5. PSILOCYBIN RESEARCH

5 36-281. Definitions

6 IN THIS ARTICLE, UNLESS THE CONTEXT OTHERWISE REQUIRES:

7 1. "ADVISORY COUNCIL" MEANS THE PSILOCYBIN RESEARCH ADVISORY  
8 COUNCIL ESTABLISHED BY SECTION 36-283.

9 2. "DEPARTMENT" MEANS THE DEPARTMENT OF HEALTH SERVICES.

10 3. "DIRECTOR" MEANS THE DIRECTOR OF THE DEPARTMENT OF HEALTH  
11 SERVICES.

12 36-282. Research grants; psilocybin research; priority; immunity

13 A. THE DIRECTOR SHALL PROVIDE FROM MONIES APPROPRIATED COMPETITIVE  
14 RESEARCH GRANTS FOR WHOLE MUSHROOM PSILOCYBIN PHASE ONE, PHASE TWO AND  
15 PHASE THREE CLINICAL TRIALS THAT ARE CAPABLE OF BEING APPROVED BY THE  
16 UNITED STATES FOOD AND DRUG ADMINISTRATION TO EVALUATE THE EFFECTS OF  
17 WHOLE MUSHROOM PSILOCYBIN ON TREATING ANY OF THE FOLLOWING:

- 18 1. POST-TRAUMATIC STRESS DISORDER.
- 19 2. SYMPTOMS ASSOCIATED WITH LONG COVID-19.
- 20 3. DEPRESSION.
- 21 4. ANXIETY DISORDERS.
- 22 5. SYMPTOMS ASSOCIATED WITH END-OF-LIFE DISTRESS.
- 23 6. OBSESSIVE COMPULSIVE DISORDER.
- 24 7. SUBSTANCE ABUSE AND ADDICTION DISORDERS.
- 25 8. EATING DISORDERS.
- 26 9. CHRONIC PAIN.
- 27 10. INFLAMMATORY DISORDERS.
- 28 11. AUTOIMMUNE DISORDERS.
- 29 12. SEIZURE DISORDERS.
- 30 13. OTHER DEGENERATIVE DISORDERS.

31 B. THE DEPARTMENT SHALL ANNOUNCE THE OPENING OF THE APPLICATION  
32 PROCESS AT LEAST THIRTY DAYS BEFORE APPLICATIONS ARE AVAILABLE AND ALLOW  
33 AT LEAST NINETY DAYS FOR APPLICANTS TO COMPLETE THEIR SUBMISSION. THE  
34 RESEARCH GRANTS SHALL BE AWARDED NOT LATER THAN JULY 1 OF EACH YEAR FOR  
35 THREE YEARS. IF IN ANY YEAR THERE IS NOT A PROPOSAL THAT MEETS THE  
36 CRITERIA FOR A RESEARCH GRANT TO BE AWARDED FOR A WHOLE MUSHROOM  
37 PSILOCYBIN CLINICAL TRIAL, THE DIRECTOR SHALL POSTPONE THE AWARD TO THE  
38 FOLLOWING YEAR.

39 C. CLINICAL TRIALS THAT ARE FUNDED PURSUANT THIS SECTION SHALL  
40 PRIORITIZE:

- 41 1. USING WHOLE MUSHROOM PSILOCYBIN CULTIVATED UNDER A SCHEDULE I  
42 LICENSE ISSUED BY THE UNITED STATES DRUG ENFORCEMENT ADMINISTRATION.
- 43 2. USING VETERANS, FIRST RESPONDERS, FRONTLINE HEALTH CARE WORKERS  
44 AND PERSONS FROM UNDERSERVED COMMUNITIES AS THE RESEARCH SUBJECTS.

45 D. NOTWITHSTANDING TITLE 13, CHAPTER 34, A PERSON WHO RECEIVES A  
46 GRANT FOR A WHOLE MUSHROOM PSILOCYBIN CLINICAL TRIAL PURSUANT TO THIS

1 SECTION AND ANY OF THE PERSON'S EMPLOYEES WORKING ON THE CLINICAL TRIAL  
2 MAY NOT BE CHARGED WITH OR PROSECUTED FOR POSSESSION OF PSILOCYBIN WHEN  
3 THE PERSON IS WORKING ON THE CLINICAL TRIAL.

4 36-283. Psilocybin research advisory council; members;  
5 recommendations

6 A. THE PSILOCYBIN RESEARCH ADVISORY COUNCIL IS ESTABLISHED IN THE  
7 DEPARTMENT CONSISTING OF THE DIRECTOR OR THE DIRECTOR'S DESIGNEE WHO IS  
8 EMPLOYED BY THE DEPARTMENT AND THE FOLLOWING MEMBERS APPOINTED BY THE  
9 DIRECTOR:

10 1. ONE MEMBER WHO HAS A FEDERAL LICENSE TO STUDY PSYCHEDELICS AND  
11 WHO IS A PHYSICIAN LICENSED PURSUANT TO TITLE 32, CHAPTER 13 OR 17.

12 2. ONE MEMBER WHO IS A MILITARY VETERAN.

13 3. ONE MEMBER WHO IS A LAW ENFORCEMENT OFFICER IN THIS STATE.

14 4. ONE MEMBER WHO IS A PROFESSOR OR RESEARCHER FROM A UNIVERSITY  
15 UNDER THE JURISDICTION OF THE ARIZONA BOARD OF REGENTS AND WHO SPECIALIZES  
16 IN CLINICAL RESEARCH OR PSYCHEDELIC STUDIES.

17 B. THE DIRECTOR SHALL SERVE AS CHAIRPERSON OF THE ADVISORY COUNCIL.

18 C. ADVISORY COUNCIL MEMBERS ARE ELIGIBLE TO RECEIVE REIMBURSEMENT  
19 OF EXPENSES PURSUANT TO TITLE 38, CHAPTER 4, ARTICLE 2.

20 D. THE ADVISORY COUNCIL SHALL:

21 1. ESTABLISH CRITERIA FOR THE CLINICAL TRIALS THAT QUALIFY TO  
22 RECEIVE RESEARCH GRANTS.

23 2. OVERSEE THE APPLICATION PROCESS AND REVIEW APPLICATIONS FOR THE  
24 CLINICAL TRIAL RESEARCH GRANTS TO ASSIST THE DIRECTOR IN SELECTING THE  
25 MOST CREDIBLE CLINICAL TRIALS TO AWARD THE RESEARCH GRANTS.

26 3. ENSURE THAT ALL ADVISORY COUNCIL MEETINGS ARE OPEN TO THE PUBLIC  
27 AND ALLOW FOR PUBLIC TESTIMONY.

28 4. ON OR BEFORE JULY 1 OF EACH YEAR, MAKE RECOMMENDATIONS TO THE  
29 GOVERNOR, THE SPEAKER OF THE HOUSE OF REPRESENTATIVES, THE PRESIDENT OF  
30 THE SENATE AND THE DEPARTMENT ON PSYCHEDELIC-ASSISTED THERAPY BASED ON  
31 CURRENT FEDERAL AND STATE RESEARCH POLICY.

32 Sec. 2. Repeal

33 Title 36, chapter 2, article 5, Arizona Revised Statutes, as added  
34 by this act, is repealed from and after December 31, 2028.

35 Sec. 3. Appropriation; department of health services;  
36 psilocybin research grants; exemption

37 A. The sum of \$30,000,000 is appropriated from the state general  
38 fund in fiscal year 2023-2024 to the department of health services for  
39 psilocybin research grants pursuant to title 36, chapter 2, article 5,  
40 Arizona Revised Statutes, as added by this act.

41 B. The appropriation made in subsection A of this section is exempt  
42 from the provisions of section 35-190, Arizona Revised Statutes, relating  
43 to lapsing of appropriations, except that any monies remaining unexpended  
44 and unencumbered on July 1, 2029 revert to the state general fund.